Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)
NCT06008249 · Stichting TRICALS Foundation · PHASE3 · terminated · last registry update 2026-05-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The planned interim analysis showed no survival benefit of taking the drug when compared with placebo.” | – | Registry record, Stichting TRICALS Foundation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IMPA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Also stopped (terminated): Dr. Inge Winter, Clozapine + Esketamine Nasal Product (NCT05603104)
- 2026-07-13Results posted on the registry: University of Michigan, a drug against IMPA1 (NCT04604314)
- 2026-05-05Results posted on the registry: Universiteit Antwerpen, Lithium (NCT06751875)
- 2026-04-14Results posted on the registry: State University of New York at Buffalo, a drug against IMPA1 (NCT06099886)
- 2026-01-29Results posted on the registry: Masonic Cancer Center, University of Minnesota, Standardized Research E-cigarette (SREC) (NCT04003805)
- 2025-10-23Also stopped (terminated): Ivoclar Vivadent AG, a drug against IMPA1 (NCT05070416)
- 2025-09-25Also stopped (terminated): Negovsky Reanimatology Research Institute, Lithium Carbonate + Placebo (NCT05126238)
- 2025-09-11Results posted on the registry: Ariel Gildengers, MD, Lithium Carbonate + Placebo oral capsule (NCT03185208)
- 2025-08-26Phase 3 first posted: Bristol-Myers Squibb, Xanomeline/Trospium Chloride + Placebo (NCT07140913)
- 2025-08-14Results posted on the registry: Ivoclar Vivadent AG, a drug against IMPA1 (NCT05070416)
- 2025-07-08Also stopped (terminated): Cancer Trials Ireland, Lithium + Oxaliplatin (NCT03153280)
- 2025-05-14Results posted on the registry: Alzamend Neuro, Inc., AL001 (NCT05363293)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision